A Curated Platform of Equity & Options Market Intelligence
Select Page

AVXL

Search by
TICKER SYMBOL

Anavex Life Sciences Corporation

Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing

9.15

-0.09

(-0.974%)

Volume:

3,982,144

52 week range:

7.36 - 15.24

Market Cap:

739.665M

Company Description:

anavex life sciences corp. is a clinical stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodevelopmental and neurodegenerative diseases. anavex is currently in a phase 2a trial for alzheimer's disease (ad) with lead therapeutic, anavex 2-73, an orally available small molecule targeting protein misfolding and cellular stress through activating the sigma-1 receptor. part a topline data of our ongoing phase 2a trial demonstrate a favorable safety, bioavailability, dose-response curve and tolerability/risk profile. anavex 2-73 is a potential platform drug showing encouraging preclinical data rare neurodevelopmental disease: rett syndrome, as well is in epilepsy and multiple sclerosis (ms). in 2015, the company was awarded a research by the michael j. fox foundation (mjff) to study anavex 2-73 for the treatment of parkinson’s disease. headquartered in new york, anavex is an american publicly traded corporation quoted as avxl.